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Abstract Few data exist regarding the healthcare and societal
burden of culture-confirmed influenza illness in European and
Israeli children. The current analysis describes this burden in
vaccinated and unvaccinated children 2–17 years of age.
Healthcare and societal burden outcomes were prospectively
collected for culture-confirmed influenza illness in three previ-
ous randomized studies: a study of live attenuated influenza
vaccine (LAIV) versus placebo in children aged <48 months
attending day care (N =846–973), and studies of LAIV versus
inactivated influenza vaccine (IIV) in children aged <72months
with recurrent respiratory infections (N =1,609) and in children
aged 6–17 years with asthma (N=2,211). The incidence of each
endpoint among enrolled subjects and subjects with influenza
was determined by treatment group and by country. Among
subjects with influenza, 57–91 % missed school or day care,
45–90 % used non-antibiotic medications, 29–55 % of parents
missed work, 17–55% used antibiotics, 11–62% had additional
provider visits, and 9–20 % had acute otitis media. Where
evaluated, rates of outcomes were generally similar between
countries. Among all children enrolled, LAIV recipients missed
324–902 and 150 fewer days of day care per 1,000 children than
those of placebo and IIV recipients, respectively; parents of
LAIV recipients missed 197–340 and 76 fewer days of work
per 1,000 children than those of placebo and IIV recipients,
respectively. Influenza illness in European and Israeli children
2–17 years of age resulted in a considerable absenteeism and
healthcare utilization that was similar across the countries
studied. These data underscore the potential benefits of annual
vaccination of children against influenza.
Introduction
Influenza is a common illness in children that results in a
significant burden on the healthcare system and society in
general. Children with influenza illness frequently require
medications and visits to healthcare providers (HCPs)
[1–15]. Pediatric influenza frequently results in complications,
the most common of which is acute otitis media (AOM),
which require additional healthcare intervention [16]. From
the societal perspective, influenza illness causes significant
absenteeism and lost productivity, with children missing
school or day care and their parents or guardians missing work
[1, 3, 4, 7, 11, 13].
An Ann Arbor strain live attenuated influenza vaccine
(LAIV) is approved for eligible children 2–17 years of age
in multiple countries, including the European Union and
Israel. However, there is ongoing debate in European coun-
tries regarding the burden of disease in this population and
whether these children should be vaccinated annually against
influenza [17].
Multiple studies have demonstrated the country-specific
burden of influenza illness in European and Israeli children
and their families [1, 3, 4, 7, 11, 13, 18]. In European coun-
tries, the incidence of confirmed influenza illness in a single
season has been shown to range from 96 to 167 per 1,000 in
children ≤14 years of age [3, 7]. However, these previous
studies were limited to a single country; there are few studies
that compare outcomes across multiple European countries
using a consistent methodology. Data from prospective, multi-
country studies are needed in order to better characterize the
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healthcare and societal burden of influenza in European and
Israeli children 2–17 years of age.
Three prospective, multi-country, randomized studies inves-
tigated the healthcare and societal burden associated with in-
fluenza in children who were vaccinated with LAIV compared
with those receiving placebo or inactivated influenza vaccine
(IIV) [18–20]. Previous publications of these studies reported
the rates of symptomatic influenza illness. However, for the
healthcare and societal burden outcomes, only the overall out-
come rates were reported, regardless of whether or not the child
had culture-confirmed influenza; the rate of health outcomes in
children with influenza was not reported. The primary aim of
our study was to use data from these studies to describe the
overall and country-specific healthcare and societal outcomes
associated with culture-confirmed influenza in vaccinated and
unvaccinated European and Israeli children 2–17 years of age.
Methods
Data sources
Data for this study were collected from three previous pro-
spective, randomized, controlled studies that evaluated the
efficacy and safety of LAIV in children in Europe and Israel.
Study 1 by Vesikari et al. [19] was a randomized, controlled
trial that examined LAIV versus placebo in 1,784 children
6–35 months of age attending day care in Belgium, Finland,
Israel, Spain, and the United Kingdom. Study subjects were
followed for two consecutive influenza seasons, between
October 2, 2000, and May 31, 2002. LAIV recipients received
two doses of LAIV separated by approximately 1 month in
year 1 and a single dose in year 2.
Study 2 by Ashkenazi et al. [20] was a randomized, con-
trolled trial that examined LAIV versus IIV in 2,187 children
6–71 months of age with recurrent respiratory tract infections
during the 2002–2003 influenza season in Belgium, the Czech
Republic, Finland, Germany, Israel, Italy, Poland, Spain,
Switzerland, and the United Kingdom. Recurrent respiratory
tract infection was defined as two or more practitioner-
attended episodes of common colds, AOM, bronchitis, pneu-
monia, or bronchiolitis in the 12 months before enrollment.
Study subjects received two doses of LAIV or IIV separated
by approximately 1 month and were followed from October 4,
2002, to June 2, 2003.
Study 3 by Fleming et al. [21] was a randomized, controlled
trial that examined LAIV versus IIV in 2,229 children 6–
17 years of age with asthma during the 2002–2003 influenza
season in Belgium, Finland, Germany, Greece, Israel, Italy, the
Netherlands, Norway, Poland, Portugal, Spain, Switzerland,
and the United Kingdom. Study subjects received one dose of
LAIVor IIVand were followed from October 4, 2002, to May
31, 2003.
Data collection
The studies prospectively evaluated all cases of respiratory
illness in enrolled subjects for the presence of influenza using
viral culture. Health outcomes were monitored by diary cards
or weekly contacts; influenza infection was monitored
through regularly scheduled telephone calls, and clinic or
home visits. Nasal swab cultures were collected if a child
had one or more of the following: AOM (suspected or diag-
nosed), fever, pneumonia, pulmonary congestion, shortness of
breath, or wheezing; or two or more of the following symp-
toms concurrently: chills, cough, decreased activity, headache,
irritability, muscle aches, pharyngitis, rhinorrhea, or vomiting.
Healthcare utilization was at the discretion of the parent or
guardian and HCP. Aside from vaccination and collection of
nasal swabs, there were no study-sponsored healthcare inter-
ventions. Investigators were blinded to the nasal swab culture
results.
For all cases of respiratory illness, the studies recorded
whether the illness resulted in various healthcare and societal
outcomes. Healthcare outcomes included the presence of
AOM (studies 1 and 2 only), medication use (antibiotic,
non-antibiotic), the number of additional unscheduled HCP
visits beyond the initial illness visit, and the number of over-
night hospitalizations (studies 2 and 3 only). Societal out-
comes included child and parental absenteeism. Child
absenteeism was measured as the percentage of children
who missed day care or school due to influenza and the
duration of the absenteeism (in days). Parental absentee-
ism data were collected only in study 1 and were
measured as the percentage of parents (of either sex)
who missed paid work to care for the participating child’s
influenza illness and the duration of this absenteeism (in
days). These were the only outcomes systematically collected
during the study. To ensure documentation of all sequelae of a
particular illness, these outcomes were recorded after illness
resolution.
Data analyses
Given differences in the study designs and populations, the
data from the three studies were analyzed separately. Analysis
was restricted to subjects who were 2 years or older at vacci-
nation. The incidence of culture-confirmed influenza and the
total days of missed school or day care (for children) or work
(for parents) per 1,000 children per season were calculated for
the per-protocol population, consistent with the original study
methods [19–21]. Healthcare and societal burden outcomes
were evaluated among children with culture-confirmed influ-
enza. All culture-confirmed influenza illnesses were evaluat-
ed, regardless of whether the influenza strains matched the
strains contained in the vaccines. Data regarding overnight
hospitalizations were not analyzed because no influenza-
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associated hospitalizations were documented in children
2 years and older. Because of the large number of influenza
cases detected in study 1, a by-country analysis of healthcare
resource use and absenteeism associated with influenza was
conducted. In this analysis, all cases regardless of the study
armwere pooled and evaluated. Fisher’s exact test was used to
test country and treatment group differences for each of these
variables. All statistical analyses were conducted using SAS,
version 8.2 (SAS Institute, Inc., Cary, NC).
Results
Demographics for all enrolled children 2–17 years of age
In study 1, 846 subjects (LAIV, n =490; placebo, n =356)
were available for analysis in year 1; in year 2, 973 subjects
were available (LAIV, n =570; placebo, n =403). For study 2,
there were 1,608 subjects (LAIV, n =790; IIV, n =818). In
study 3, 2,211 subjects were available (LAIV, n =1,114; IIV,
n =1,115). In all studies, the study arms were well balanced
for gender and race (Table 1).
Rates of influenza among all enrolled children 2–17 years
of age
During the first year of study 1, influenza illness was con-
firmed in 16 % of placebo recipients (n =55) and 2 % of
subjects vaccinated with LAIV (n =11). During the second
year of study 1, influenza illness was confirmed in 31 % of
placebo recipients (n =123) and 4 % of LAIV recipients
(n =21). For study 2, 3 % of subjects who received LAIV
(n =23) experienced confirmed influenza illness compared
with 6 % of subjects vaccinated with IIV (n =46). For study 3,
5 % of subjects who received LAIV (n =50) experienced
confirmed influenza illness compared with 7 % of IIV
recipients (n =73).
Healthcare and societal outcomes among children 2–17 years
of age with influenza
In study 1, healthcare outcomes were frequent among placebo
and LAIV recipients with influenza (Fig. 1). Most subjects
missed school or day care and received medications. In year 1,
the mean number of missed day care days for those children
absent due to influenza was 3.1 and 3.2 for LAIVand placebo
recipients, respectively. In year 2, the mean durations were 2.6
and 3.6 days, respectively. Approximately one-half of subjects
with influenza required a parent to miss work for the child’s
illness. In years 1 and 2, the mean number of parental missed
work days for parents who missed work due to their child’s
illness was 1.8 and 2.3 for LAIV recipients and 2.8 and 2.7
placebo recipients, respectively. Additional HCP visits after
the initial study visit were more frequent in year 1 when
subjects were younger. In year 2, the percentages of subjects
requiring parental missed work and additional HCP
visits were lower in LAIV recipients, but these differences
were not statistically significant (p =0.23 and p =0.08,
respectively).
The proportion of influenza-positive subjects with these
outcomes was generally similar in each country (Fig. 2).
However, non-antibiotic medication use was less common in
Finland and Israel than it was in Belgium, Spain, and the United
Kingdom. Additionally, parental missed work was less com-
mon in Belgium and Spain. These trends were present in both
study years and were statistically significant (p <0.001) in the
Table 1 Baseline demographics by study and treatment
Study 1 (24–47 months of age) Study 2 (24–71 months of age) Study 3 (6–17 years of age)
Year 1 Year 2
LAIV Placebo LAIV Placebo LAIV IIV LAIV IIV
Number of subjects 490 356 570 403 790 818 1114 1115
Gender, n (%)
Male 264 (53.9) 188 (52.8) 304 (53.3) 195 (48.4) 409 (51.8) 431 (52.7) 694 (62.3) 723 (64.8)
Female 226 (46.1) 168 (47.2) 266 (46.7) 208 (51.6) 381 (48.2) 387 (47.3) 420 (37.7) 392 (35.2)
Race/ethnicity, n (%)
White 474 (96.7) 344 (96.6) 555 (97.4) 393 (97.5) 769 (97.3) 788 (96.3) 1,091 (97.9) 1,089 (97.7)
Black 4 (0.8) 2 (0.6) 6 (1.1) 2 (0.5) 11 (1.4) 9 (1.1) 9 (0.8) 8 (0.7)
Asian 3 (0.6) 2 (0.6) 4 (0.7) 1 (0.3) 5 (0.6) 13 (1.6) 10 (0.9) 6 (0.5)
Other 9 (1.8) 8 (2.3) 5 (0.9) 7 (1.7) 5 (0.6) 8 (1.0) 4 (0.4) 12 (1.1)
Number of subjects with influenza 11 55 21 123 23 46 50 73
IIV trivalent inactivated influenza vaccine, LAIV live attenuated influenza vaccine
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pooled analysis of years 1 and 2. The differences did not appear
to be due to differences in the age of subjects with influenza in
the countries, because the mean age for influenza cases
by country was 28–31 months in year 1 and 34–38 months in
year 2.
In studies 2 and 3, child absenteeism and non-antibiotic
medication use were the most common outcomes (Fig. 3). In
study 2, AOMwas reported in 9 % of subjects with confirmed
influenza in both treatment groups; AOMwas not collected in
study 3. In study 2, the mean number of missed school days
for those children absent due to influenza was 3.0 and 4.3 days
for LAIVand IIV recipients, respectively. In study 3, the mean
number of missed school days for those children absent due to
influenza was 3.8 and 3.7 days for LAIV and IIV recipients,
respectively.
Influenza-associated absenteeism among all enrolled children
2–17 years of age
Given the potential societal benefits of reductions in influenza-
associated absenteeism, the number of days of absenteeism per
1,000 children enrolled was evaluated for each study. In years 1
and 2 of study 1, respectively, LAIV recipients missed 324 and
902 fewer days of day care per 1,000 children than placebo
Fig. 1 Healthcare resource use
and absenteeism by year and





Fig. 2 Healthcare resource use
and absenteeism by country in
study 1 (years 1 and 2 combined)
among children with confirmed
influenza. *p <0.001, p-values
were calculated using Fisher’s
exact test to assess differences
among countries.
HCP=healthcare provider
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recipients (p<0.001), representing an 84 to 92 % reduction in
missed day care days, respectively (Fig. 4a). Parents of LAIV
recipients missed 197 (year 1) and 340 (year 2) fewer days of
work per 1,000 children compared with parents of placebo
recipients (p <0.001), representing a 90 to 93 % reduction,
respectively (Fig. 4a). In study 2, LAIV recipients missed 150
fewer days of day care/school due to influenza per 1,000
children compared with IIV recipients (p <0.01), representing
a 75% reduction in missed days of day care/school (Fig. 4b). In
study 3, LAIV recipients missed 76 fewer days of school/work
per 1,000 children than IIV recipients (p =0.02), representing a
35 % reduction.
Discussion
This analysis of data from three large clinical studies provides
additional insight into the vaccine-preventable annual
healthcare and societal burden of influenza for children and
their families in Europe and Israel. Among children who de-
veloped influenza illness, most missed school or day care and
required medications, demonstrating that the influenza illness
events evaluated in the studies represented clinically and soci-
etally meaningful illness. Additionally, in studies 2 and 3,
which had similar designs and were conducted during the same
influenza season, the rates of the measured outcomes were
Fig. 3 Healthcare resource use
and absenteeism by treatment in







absenteeism among all children
enrolled per 1,000 children per
season. a Study 1. b Studies 2
and 3. IIV=trivalent inactivated
influenza vaccine; LAIV=live
attenuated influenza vaccine.
*p <0.001, LAIV versus
comparator; †p =0.02,
LAIV versus IIV
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similar among younger (2–6 years of age) and older (6–17 years
of age) children. Community-based studies among European
children have demonstrated a similar healthcare and societal
burden of influenza, with 28–43 % of children with confirmed
influenza illness receiving antibiotics, 99 % receiving antipy-
retic medications, 11–41 % developing AOM, and 22–50 % of
children requiring a parent to miss work, with an average
absenteeism of 2.8–4.5 days [3, 7, 22].
The current analysis provides a valuable multi-country
description of healthcare resource use and absenteeism asso-
ciated with pediatric influenza illness. Few European studies
have evaluated with consistent methods the burden of influ-
enza across multiple countries in the same influenza seasons
[23]. The current analysis demonstrated that the burden of
influenza was generally similar across multiple European
countries. However, patients in Finland and Israel used less
non-antibiotic medications and parents in Spain and Belgium
missed fewer work days than in other countries. These dis-
crepancies may reflect cultural differences in medical practice
and child care. Despite these observed differences, the ob-
served outcomes suggest that the healthcare and societal bur-
den of pediatric influenza is generally similar across European
countries.
Although multiple European studies have described child
and parental absenteeism associated with influenza [1, 3, 4, 7,
11, 13, 22, 24, 25], only a single previous European study has
evaluated the incidence rate of child absenteeism in a
community-based cohort. In Finland during 2000–2002,
75 % of children with influenza illness missed school or day
care, with an average absenteeism of 3.4 days. Additionally, a
parent missed at least 1 day of work in 49.4 % of pediatric
influenza illnesses, with absenteeism averaging 2.7 days [7].
The current analysis provides valuable estimates of the inci-
dence of absenteeism among children with influenza illness
for additional European countries.
Relative to placebo and IIV, LAIV was associated with
considerable reductions in the number of missed day care or
school days and parental missed work. A previous U.S. study
of LAIV relative to placebo also demonstrated that influenza-
associated fever, otitis media, missed school or day care days,
missed parental work days, and HCP visits decreased by 86 %
to 98% during seasons in which the circulating strains matched
[26] and did not match [27] the strains contained in the vaccine.
Similarly, in the placebo-controlled study in this analysis, for
every ten children attending day care whowere vaccinated with
LAIV, there were approximately six fewer days of missed
school or day care, three fewer days of parental missed work,
and one less additional HCP visit beyond the initial influenza
illness visit. These data further highlight the potential healthcare
and societal benefits of annual influenza vaccination in children
and provide reassurance that, by reducing the incidence of
influenza illness, LAIV can also reduce the healthcare and
societal burden impact of influenza illness.
The primary limitation of the current analysis is that the
studies were conducted during three influenza seasons, which
may not be representative of the average burden of influenza
in Europe and Israel. However, while the absolute incidence
of influenza in children can vary considerably by season,
vaccine efficacy and the rate of complications and sequelae
among those with influenza have been shown to be similar
across seasons [3, 7, 22, 28, 29]. Additionally, the studies did
not collect the actual costs associated with the healthcare and
societal burden outcomes.
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